238 related articles for article (PubMed ID: 16266359)
1. An open-label study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy.
Herrmann DN; Barbano RL; Hart-Gouleau S; Pennella-Vaughan J; Dworkin RH
Pain Med; 2005; 6(5):379-84. PubMed ID: 16266359
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy.
Barbano RL; Herrmann DN; Hart-Gouleau S; Pennella-Vaughan J; Lodewick PA; Dworkin RH
Arch Neurol; 2004 Jun; 61(6):914-8. PubMed ID: 15210530
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale.
Argoff CE; Galer BS; Jensen MP; Oleka N; Gammaitoni AR
Curr Med Res Opin; 2004; 20 Suppl 2():S21-8. PubMed ID: 15563743
[TBL] [Abstract][Full Text] [Related]
4. Skin biopsy and quantitative sensory testing do not predict response to lidocaine patch in painful neuropathies.
Herrmann DN; Pannoni V; Barbano RL; Pennella-Vaughan J; Dworkin RH
Muscle Nerve; 2006 Jan; 33(1):42-8. PubMed ID: 16228968
[TBL] [Abstract][Full Text] [Related]
5. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale.
Gammaitoni AR; Galer BS; Onawola R; Jensen MP; Argoff CE
Curr Med Res Opin; 2004; 20 Suppl 2():S13-9. PubMed ID: 15563742
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults.
Kivitz A; Fairfax M; Sheldon EA; Xiang Q; Jones BA; Gammaitoni AR; Gould EM
Clin Ther; 2008 Dec; 30(12):2366-77. PubMed ID: 19167595
[TBL] [Abstract][Full Text] [Related]
7. Topical pain management with the 5% lidocaine medicated plaster--a review.
Mick G; Correa-Illanes G
Curr Med Res Opin; 2012 Jun; 28(6):937-51. PubMed ID: 22551228
[TBL] [Abstract][Full Text] [Related]
8. An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy.
Simpson DM; Estanislao L; Brown SJ; Sampson J
J Pain Symptom Manage; 2008 Mar; 35(3):299-306. PubMed ID: 17959343
[TBL] [Abstract][Full Text] [Related]
9. Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain.
Galer BS; Gammaitoni AR; Oleka N; Jensen MP; Argoff CE
Curr Med Res Opin; 2004; 20 Suppl 2():S5-12. PubMed ID: 15563741
[TBL] [Abstract][Full Text] [Related]
10. Lidocaine patch 5 for carpal tunnel syndrome: how it compares with injections: a pilot study.
Nalamachu S; Crockett RS; Mathur D
J Fam Pract; 2006 Mar; 55(3):209-14. PubMed ID: 16510054
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds.
Affaitati G; Fabrizio A; Savini A; Lerza R; Tafuri E; Costantini R; Lapenna D; Giamberardino MA
Clin Ther; 2009 Apr; 31(4):705-20. PubMed ID: 19446144
[TBL] [Abstract][Full Text] [Related]
12. Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study.
Thisted RA; Klaff L; Schwartz SL; Wymer JP; Culligan NW; Gerard G; Pope LE; Berg JE
Clin Ther; 2006 Oct; 28(10):1607-18. PubMed ID: 17157116
[TBL] [Abstract][Full Text] [Related]
13. Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis.
Galer BS; Sheldon E; Patel N; Codding C; Burch F; Gammaitoni AR
Curr Med Res Opin; 2004 Sep; 20(9):1455-8. PubMed ID: 15383194
[TBL] [Abstract][Full Text] [Related]
14. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain.
Ho KY; Huh BK; White WD; Yeh CC; Miller EJ
Clin J Pain; 2008 Jan; 24(1):51-5. PubMed ID: 18180637
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a metered-dose 8% lidocaine pump spray for patients with post-herpetic neuralgia.
Kanai A; Kumaki C; Niki Y; Suzuki A; Tazawa T; Okamoto H
Pain Med; 2009; 10(5):902-9. PubMed ID: 19682274
[TBL] [Abstract][Full Text] [Related]
16. Patient perceptions associated with the 5% lidocaine medicated plaster in daily practice.
Überall MA; Müller-Schwefe GH
Curr Med Res Opin; 2012 Jun; 28(6):901-9. PubMed ID: 22506624
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of neuropathic pain with a 5% lidocaine medicated plaster.
Wilhelm IR; Tzabazis A; Likar R; Sittl R; Griessinger N
Eur J Anaesthesiol; 2010 Feb; 27(2):169-73. PubMed ID: 20010108
[TBL] [Abstract][Full Text] [Related]
18. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
19. Symptom profiles differ in patients with neuropathic versus non-neuropathic pain.
Dworkin RH; Jensen MP; Gammaitoni AR; Olaleye DO; Galer BS
J Pain; 2007 Feb; 8(2):118-26. PubMed ID: 16949878
[TBL] [Abstract][Full Text] [Related]
20. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial.
Katz NP; Gammaitoni AR; Davis MW; Dworkin RH;
Pain Med; 2002 Dec; 3(4):324-32. PubMed ID: 15099237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
